Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2024 fredag den 23. august 2024
August 14, 2024 05:58 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) af 2024 om morgenen fredag den 23. august 2024. ALK afholder senere samme dag kl. 13.30 (CEST) en præsentation...
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
August 14, 2024 05:58 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors...
ALK opjusterer forventningerne til omsætning og indtjening i 2024
June 21, 2024 12:43 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at forventningerne til helåret er blevet opjusteret som følge af bedre end forventet salgsudvikling i andet kvartal og forbedrede udsigter for...
ALK upgrades its full-year revenue and earnings outlook
June 21, 2024 12:43 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the...
ALK giver opdatering på registreringsprocessen for tabletten mod husstøvmideallergi i Kina
June 21, 2024 12:38 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at selskabet har besluttet at trække sin registreringsansøgning for tabletten mod husstøvmideallergi. ALK vil fortsat samarbejde med...
ALK provides update on regulatory process for the house dust mite allergy tablet in China
June 21, 2024 12:38 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in...
ALK lancerer ny vækststrategi og finansielle ambitioner for 2028
June 03, 2024 12:02 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag meddelt, at bestyrelsen har vedtaget en ny selskabsstrategi (Allergy+) og finansielle ambitioner for 2028. Målet med Allergy+ er at udbygge ALK’s...
ALK launches new growth strategy and 2028 financial ambitions
June 03, 2024 12:02 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen...
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
June 03, 2024 01:00 ET
|
ALK Abello
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK...
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
May 30, 2024 07:44 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for...